Preferred Pricing for Remicade®

Another Way to Save on Drug Plan Costs

Communiqué

This communication is intended for plan members who reside outside Quebec and if the drug plan offers a direct payment program.


iA Financial Group is committed to delivering ongoing value to our clients and to lowering the drug costs for employers and their employees. 


We are pleased to announce that since July 1, 2015, in collaboration with Express Scripts Canada (ESC), we are able to offer a rebate on the cost of the drug Remicade®. 

Remicade® is a specialty drug approved for the treatment of multiple inflammatory conditions including: 
  • gastrointestinal conditions (ulcerative colitis, Crohn’s disease) 
  • dermatological conditions (plaque psoriasis) 
  • rheumatologic diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) 
All stakeholders, plan members and plan sponsors (outside of the province of Quebec) would benefit from the discounted price of Remicade®. The discount applies as long as the claims are electronically adjudicated at any pharmacy by using the iA benefit card (direct payment program only) and that iA is the first payer.

iA Financial Group continues to work on future drug cost management initiatives to help plan sponsors keep their drug plan costs stable while offering plan members drug cost savings.

If you have any questions or concerns regarding this announcement, please contact your benefits advisor or your iA Financial Group account executive.